- Home
- DMA vs PLX Comparison
DMA vs PLX Comparison
Compare DMA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMA
- PLX
- Stock Information
- Founded
- DMA 2011
- PLX 1993
- Country
- DMA United States
- PLX United States
- Employees
- DMA N/A
- PLX N/A
- Industry
- DMA Trusts Except Educational Religious and Charitable
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DMA Finance
- PLX Health Care
- Exchange
- DMA Nasdaq
- PLX Nasdaq
- Market Cap
- DMA 77.5M
- PLX 122.6M
- IPO Year
- DMA N/A
- PLX 1998
- Fundamental
- Price
- DMA $8.64
- PLX $1.43
- Analyst Decision
- DMA
- PLX Strong Buy
- Analyst Count
- DMA 0
- PLX 1
- Target Price
- DMA N/A
- PLX $15.00
- AVG Volume (30 Days)
- DMA 34.6K
- PLX 1.3M
- Earning Date
- DMA 01-01-0001
- PLX 08-13-2025
- Dividend Yield
- DMA 2.04%
- PLX N/A
- EPS Growth
- DMA N/A
- PLX N/A
- EPS
- DMA N/A
- PLX 0.05
- Revenue
- DMA N/A
- PLX $59,764,000.00
- Revenue This Year
- DMA N/A
- PLX $65.02
- Revenue Next Year
- DMA N/A
- PLX $57.34
- P/E Ratio
- DMA N/A
- PLX $29.48
- Revenue Growth
- DMA N/A
- PLX 0.18
- 52 Week Low
- DMA $4.78
- PLX $0.82
- 52 Week High
- DMA $8.00
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- DMA 46.28
- PLX 41.06
- Support Level
- DMA $8.58
- PLX $1.43
- Resistance Level
- DMA $8.77
- PLX $1.54
- Average True Range (ATR)
- DMA 0.11
- PLX 0.11
- MACD
- DMA -0.01
- PLX 0.02
- Stochastic Oscillator
- DMA 25.09
- PLX 28.57
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.